# A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

> **NCT00117117** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 2423 (—)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Aranesp

## Key facts

- **NCT ID:** NCT00117117
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2003-12
- **Target enrollment:** 2423 (—)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117117, "A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00117117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*